These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 28341110)
21. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y; Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428 [TBL] [Abstract][Full Text] [Related]
22. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts. Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869 [TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure. Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956 [TBL] [Abstract][Full Text] [Related]
24. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Russo A; Franchina T; Ricciardi GR; Picone A; Ferraro G; Zanghì M; Toscano G; Giordano A; Adamo V Oncotarget; 2015 Sep; 6(29):26814-25. PubMed ID: 26308162 [TBL] [Abstract][Full Text] [Related]
25. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920 [TBL] [Abstract][Full Text] [Related]
26. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma. Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211 [TBL] [Abstract][Full Text] [Related]
27. [Biological diagnosis of resistance to erlotinib in a malignant pleural effusion]. Rieux C; Boisdron-Celle M; Morel A; Fey L; Urban T; Hureaux J Rev Mal Respir; 2013 Sep; 30(7):572-5. PubMed ID: 24034463 [TBL] [Abstract][Full Text] [Related]
29. Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection? Ulivi P; Delmonte A; Chiadini E; Calistri D; Papi M; Mariotti M; Verlicchi A; Ragazzini A; Capelli L; Gamboni A; Puccetti M; Dubini A; Burgio MA; Casanova C; Crinò L; Amadori D; Dazzi C Int J Mol Sci; 2014 Dec; 16(1):747-57. PubMed ID: 25561229 [TBL] [Abstract][Full Text] [Related]
30. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003 [TBL] [Abstract][Full Text] [Related]
31. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression. van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272 [TBL] [Abstract][Full Text] [Related]
32. Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs. Li J; Wang Z; Groen HJM; Zhao J; Wang P; Zhang C; Yang K; Guo Y; Ma J Lung Cancer; 2018 Apr; 118():173-175. PubMed ID: 29502892 [No Abstract] [Full Text] [Related]
33. [Mutation testing for non-small-cell lung cancer]. Brustugun OT; Helland Å; Fjellbirkeland L; Kleinberg L; Ariansen S; Jebsen P; Scott H; Dønnem T; Bremnes R; Berg T; Grønberg BH; Dai HY; Wahl SG; Mangseth K; Helgeland L Tidsskr Nor Laegeforen; 2012 Apr; 132(8):952-5. PubMed ID: 22562326 [TBL] [Abstract][Full Text] [Related]
34. Rapid screening for EGFR mutations: pros and cons. Gazdar AF Cancer J; 2006; 12(1):17-8. PubMed ID: 16613656 [No Abstract] [Full Text] [Related]
35. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer. Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221 [TBL] [Abstract][Full Text] [Related]
36. Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes. Fraser A N Z Med J; 2017 Mar; 130(1451):11-20. PubMed ID: 28253240 [TBL] [Abstract][Full Text] [Related]
37. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108 [TBL] [Abstract][Full Text] [Related]
38. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. Bronte G; Franchina T; Alù M; Sortino G; Celesia C; Passiglia F; Savio G; Laudani A; Russo A; Picone A; Rizzo S; De Tursi M; Gambale E; Bazan V; Natoli C; Blasi L; Adamo V; Russo A Oncotarget; 2016 Jun; 7(24):35803-35812. PubMed ID: 26993607 [TBL] [Abstract][Full Text] [Related]
39. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors. Kashima J; Okuma Y; Miwa M; Hosomi Y Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781 [TBL] [Abstract][Full Text] [Related]
40. Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population. Sluga R; VAN DEN Borne BEEM; Roepman P; Peters BJM; Kastelijn EA; Schramel FMNH Anticancer Res; 2018 Jan; 38(1):393-400. PubMed ID: 29277800 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]